NCT05270746 (RVS-ICAS) is a clinical trial in Intracranial Stenosis, sponsored by Capital Medical University.

Who is sponsoring NCT05270746?

NCT05270746 is sponsored by Capital Medical University.

What condition does NCT05270746 study?

NCT05270746 studies Intracranial Stenosis.

Is NCT05270746 still recruiting?

NCT05270746 is currently status unknown. Last updated 8 March 2022.

Last reviewed 2022-03-08 · How we verify

NCT05270746: RVS-ICAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Predictive Value of Retinal Vascular Signs for Intracranial Artery Stenosis (RVS-ICAS)

Status unknown Last updated 8 March 2022

What this trial tests

trial in Intracranial Stenosis in 1,000 participants. Status unknown.

Timeline

27 February 2022

Primary endpoint
26 June 2022

1 July 2022

Quick facts

Lead sponsor	Capital Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	27 February 2022
Primary completion	26 June 2022
Estimated completion	1 July 2022
Sites	2 locations across China

Conditions studied

Intracranial Stenosis — all drugs for Intracranial Stenosis →

Sponsor

Capital Medical University

Who can join

35 and older, any sex, with Intracranial Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intracranial artery stenosis (ICAS) is a leading cause of ischemic stroke worldwide, contributing to the global burden of stroke, particularly in the Asian population. However, there is no non-invasive, easy to popularize and economic for intracranial artery stenosis in mass population screening. This study aims to evaluate the predictive value of retinal vascular signs for intracranial artery stenosis (ICAS) and explore a new screening method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intracranial Stenosis

Currently open trials in the same condition.

NCT07072026 — Endovascular Recanalization for Symptomatic Chronic Intradural Occlusions · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05270746 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 8 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing